Tag: entrance
-
GSK asthma drug Nucala’s long-term study supports safety profile
(Reuters) – GlaxoSmithKline Plc said on Saturday its asthma drug, Nucala, which is already approved in the United States and Europe, showed a similar safety profile in a long-term study compared with previous studies. GSK said Nucala, which is administered once every four weeks by injection, maintained its risk/benefit profile over an extended 52-week period.…
-
Brexit is the wrong prescription, says European pharma industry
By Ben Hirschler LONDON (Reuters) – Britain's departure from the European Union would threaten scientific research and jeopardize the 28-nation bloc's system of drug regulation, the European pharmaceutical industry said on Wednesday. The declaration is the clearest statement yet on the issue by an industry that includes EU-based players such as Britain's GlaxoSmithKline and AstraZeneca,…